INTRODUCTION
In human platelets, increases in cAMP or cGMP inhibit agonistinduced platelet aggregation [1] [2] [3] [4] . Intracellular concentrations of cyclic nucleotides are tightly controlled by the activities of adenylate and guanylate cyclases and various phosphodiesterases (PDEs). Three distinct forms of PDEs were initially isolated by DEAE-cellulose chromatography of platelet extracts [5] . Further studies in platelets led to the identification and purification of a low-K m cAMP PDE that was competitively inhibited by cGMP [6, 7] , a cGMP-binding cGMP PDE [8, 9] and a cGMP-stimulated PDE that hydrolyses both cAMP and cGMP [10] . Seven mammalian PDE gene families have now been recognized and classified according to substrate affinities, inhibitor sensitivities, modes of regulation and primary sequence homology, and a standardized nomenclature for these enzymes has now been adopted [11] . According to this classification, platelet cGMPinhibited phosphodiesterase (cGI-PDE), cGMP-stimulated phosphodiesterase and cGMP-binding phosphodiesterase are members of the PDE3, PDE2 and PDE5 gene families respectively. Hydrolysis of cGMP results predominantly from PDE5, an enzyme possessing a high K m for cAMP and a low K m for cGMP. Although PDE2 and PDE3 enzymes both hydrolyse cAMP, they are differentially regulated by cGMP. PDE2, for instance, is stimulated by cGMP through an allosteric binding site, whereas PDE3 is competitively inhibited by cGMP, which is hydrolysed very slowly. In platelets, the PDE3 enzyme is the Abbreviations used : RT, reverse transcriptase ; PDE, phosphodiesterase ; TBS, Tris-buffered saline ; cGI-PDE, cGMP-inhibited phosphodiesterase ; HEL, human erythroleukaemia ; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine.
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99p1 nM respectively) were significantly lower than those for immunoprecipitates of intact platelet PDE3 (398p50 nM and 252p16 nM respectively). Moreover, N-terminal truncations of platelet enzyme increased the ratio of V max for cGMP\V max for cAMP from 0.16p0.01 in intact platelet enzyme, to 0.37p0.05 in cGI-PDE∆1 and to 0.49p0.04 in cGI-PDE∆2. Thus deletion of the N-terminus enhanced hydrolysis of cGMP relative to cAMP, suggesting that N-terminal sequences may exert selective effects on enzyme activity. Removal of the 44-amino-acid insert generated a mutant with a catalytic domain closely resembling those of other PDE gene families but despite a limited ability to be photolabelled by [$#P]cGMP, no cyclic nucleotide hydrolytic activities of the mutant were detectable. Mutation of amino acid residues in putative β-turns at the beginning and end of the 44-amino-acid insert to alanine residues markedly reduced the ability of the enzyme to hydrolyse cyclic nucleotides. The PDE3 inhibitor, lixazinone, retained the ability to inhibit cAMP hydrolysis and [$#P]cGMP binding by the N-terminal deletion mutants and the site-directed mutants, suggesting that PDE3 inhibitors may interact exclusively with the catalytic domain of the enzyme.
major cAMP PDE and is thought to account for 80 % of the hydrolysis at sub-micromolar concentrations of cAMP [12] . Increases in platelet cAMP attributed to the inhibition of PDE3 by cGMP, have been shown to account for the synergistic inhibition of platelet aggregation by activators of guanylate and adenylate cyclases [13] . All PDEs contain a conserved 270-amino-acid segment located in the carboxy terminus of the molecule which encompasses the catalytic domain of the enzyme [14, 15] . The highly divergent amino-terminal regions of the PDE molecules are likely to confer some of the distinctive regulatory properties characteristic of the individual PDE gene families. cDNAs encoding two distinct cGMP-inhibited PDEs have been previously cloned from a human cardiac cDNA library (PDE3A) [16] and a rat adipocyte cDNA library (PDE3B) [17] . Both PDE3A and PDE3B possess a common domain organization [18] . The deduced amino acid sequences of these two subfamily members indicate a high degree of homology (88 %) at the C-terminal catalytic region and a significant amount of divergence at the N-terminus. Located within the catalytic domain is a 44-amino-acid insert which is characteristic of the PDE3 gene family. Although the function of this insert is not known, it could play a role in substrate binding or interaction with PDE3-specific inhibitors. In this study, we have used reverse transcriptase PCR (RT-PCR) to clone the Cterminal half of human platelet cGI-PDE. The resulting truncation mutant, cGI-PDE∆1 was expressed in Escherichia coli, purified for kinetic and pharmacological analysis and compared with the intact platelet enzyme. The effects of deletion and sitedirected mutagenesis of the 44-amino-acid insert were also studied. 
EXPERIMENTAL

Preparation of platelet soluble proteins
Human platelets were first isolated and washed in Ca# + -free Tyrode's solution supplemented with 5 mM Pipes, pH 6.5, 50 units of heparin\ml, 75 µg of apyrase\ml and 3.5 mg of BSA\ml as described by Mustard et al. [19] . After centrifugation at 1000 g for 15 min, the platelets were finally resuspended at 2.5i10*\ml in Buffer A (100 mM KCl, 2.5 mM EGTA, 25 mM Hepes, pH 7.4, and 0.2 mM leupeptin), frozen in 1 ml aliquots using a solid-CO # \methanol bath and stored at k70 mC. When required, the platelets were thawed and sonicated on ice for 4i30 s ; soluble proteins were obtained by centrifugation at 100 000 g for 1 h. These proteins were used either for photolabelling or for immunoprecipitation (see below).
Reverse transcriptase PCR
Human platelet mRNA was isolated using the FastTrack mRNA Isolation kit (Invitrogen, San Diego, CA, U.S.A.) according to the manufacturer's instructions. Platelet cDNA was then prepared using Superscript reverse transcriptase (Gibco\BRL, Burlington, ON, Canada) and an oligo(dT) primer (1 h at 37 mC), after which the sample was heated to 99 mC for 5 min to inactivate the enzyme. Degenerate primers, each with two 5h restriction sites (in bold) were designed based on the sequences of peptides isolated from platelet cGI-PDE, and also found in the cloned human cardiac enzyme [16] (forward primer : 5h-GGTC-TAGAGGATCC(C\A\T\G)GA(G\A)AC(A\T\C\G)ATGA-TGTT-3h, corresponding to amino acid residues 661-666 of the cardiac PDE3 ; reverse primer : 5h-GGGAATTCGTCGAC(G\A)-AA(G\A)TC(G\A)AA(G\A)TG(C\T)TT-3h, corresponding to amino acid residues 911-917). An 800 bp PCR product generated using these primers and platelet cDNA as a template was purified by low-melting-point agarose-gel electrophoresis (FMC BioProducts, Rockland, ME, U.S.A.), cloned into pBluescript II Figure 1 Cloning strategy for the generation of platelet cGI-PDE deletion mutants and the specific removal of the 44-amino-acid insert from the catalytic domain (a) A 1.8 kb region of platelet cGI-PDE was amplified using RT-PCR and platelet mRNA. The PCR product (see photograph of agarose gel), which coded for the complete catalytic domain of cGI-PDE, was cloned into pBluescript II SK + for sequencing and then subcloned into the bacterial expression vector pQE-30. The His 6 -tagged protein, representing a truncated form of the human platelet cGI-PDE (cGI-PDE∆1), was expressed to high levels in E. coli. (b) The 44 amino acid insert characteristic of the PDE3 family was specifically removed from cGI-PDE∆1 using a PCR approach, to give cGI-PDE∆1∆i. Primers 1 and 3 were used to amplify the region upstream of the insert and primers 2 and 4 to amplify the downstream region. By incorporating an Afl II restriction site into primers 3 and 4, the boundary formed by the ligation of these two regions produced the required PILS amino acid sequence. Diagonal shading, catalytic domain ; solid area, 44-amino-acid insert ; horizontal shading, His 6 sequence from vector. Ab, antibody binding site.
SK + (Stratagene, La Jolla, CA, U.S.A.) and sequenced in both directions using Sequenase Version 2 (Amersham, Oakville, ON, Canada). PCR reaction conditions using Taq DNA polymerase were : first five cycles, denaturation for 1 min at 95 mC, annealing for 2 min at 45 mC and extension for 1.5 min at 65 mC, followed by 25 cycles of 1 min at 95 mC, 2 min at 65 mC, and 1.5 min at 72 mC, with a final extension step of 10 min at 72 mC.
Following demonstration that this PCR fragment was identical in sequence with human cardiac cGI-PDE (PDE3A) cDNA, sequence-specific forward and reverse primers were selected to amplify the C-terminal half of the platelet cDNA, including the whole of the catalytic domain (Figure 1a ). This truncation mutant (cGI-PDE∆1) was generated with primers 1 and 2, constructed with BamHI and EcoRI restriction sites respectively (forward : 5h-TAGGATCCCACAGGGCCTTAACTTACACT-Platelet cGMP-inhibited phosphodiesterase CAG-3h ; and reverse : 5h-TCGAATTCGGTACCATTGTCAC-TGGTCTGGCT-3h), yielding sequence corresponding to amino acids 560-1141 of the cardiac enzyme. In addition, a shorter truncation mutant (cGI-PDE∆2) was generated using the forward degenerate primer to yield sequence corresponding to amino acid residues 659-1141.
Removal of the 44-amino-acid insert characteristic of the PDE3 family (shown in black) from the catalytic domain of cGI-PDE∆1 was achieved using a PCR approach (Figure 1b) . Regions upstream and downstream of this insert were selectively amplified, purified on a low-melting-point agarose gel, and ligated to generate a mutant, cGI-PDE∆1∆i. To conserve the amino acid sequence, PILS, at the site of ligation, AflII restriction sites were incorporated into PCR primers 3 and 4 ( Figure 1b ). For construction of the above deletion mutants, the PCR profile consisted of 25 cycles containing denaturation at 95 mC for 1 min, primer annealing at 58 mC for 2 min and chain extension at 65 mC for 1.5 min. The extension step of the final cycle was increased to 10 min at 72 mC. All PCR products were purified, cloned and sequenced in pBluescript II SK + , as above.
Expression and purification of fusion proteins
cGI-PDE deletion mutants were subcloned into the BamHI and KpnI restriction sites of the bacterial expression vector pQE-30 (Qiagen, Chatsworth, CA, U.S.A.) to yield fusion proteins with an N-terminal MRGSH ' GS sequence. The E. coli M15 strain transformed with this plasmid were grown to an attenuation of 0.5-0.6 before being induced with 0.5 mM isopropyl thiogalactopyranoside. After growth at 30 mC for an additional 4 h, the cells were harvested and resuspended either in Buffer B (50 mM NaH # PO % , pH 7.8, 300 mM NaCl, 1 mM PMSF, 0.2 mM leupeptin) for isolation of His ' -tagged protein by nickelresin chromatography, or in Buffer C (100 mM Hepes, pH 7.5, 2 mM EGTA, 0.2 mM leupeptin) for immunoprecipitation of protein. In both cases, bacterial suspension was sonicated on ice for 4i30 s and centrifuged at 100 000 g for 1 h. Supernatant proteins in Buffer B were loaded on to a nickel-resin column to bind the histidine-containing fusion protein. Contaminating proteins were removed by washing with Buffer B containing increasing concentrations of imidazole (5, 80 and 100 mM). Intact His ' -tagged protein was then eluted using Buffer B containing 500 mM imidazole. The eluant was dialysed overnight against Buffer C to remove imidazole before enzymic analysis. Alternatively, the expressed protein was immunoprecipitated from bacterial supernatant proteins in Buffer C using anti-PDE3A IgG, affinity-purified on Avid gel (BioProbe Inc., Tustin, CA, U.S.A.). Protein samples (100 µl) were incubated for 90 min with 20-30 µl of IgG at 0 mC, and were then shaken for 90 min at 4 mC with 50 µl of 50% Protein A-Sepharose. The Protein A-Sepharose was isolated by centrifugation (12 000 g, 2 min), washed three times with Buffer C, and resuspended in an appropriate volume of Buffer C for assay of cAMP and cGMP PDE activities.
Site-directed mutagenesis of cGI-PDE∆1
Mutagenesis was performed according to the 2-step PCR protocol of Landt et al. [20] with minor modifications. Briefly, an intermediate PCR product was first generated using a 5h sequencespecific primer and a 3h mutagenic primer containing the modified deoxynucleotides. This fragment was purified on a low-meltingpoint agarose gel and used as the 5h mutagenic primer in a second PCR reaction with a 3h sequence-specific primer. The sequence-specific primers were 5h and 3h to unique restriction sites present in cGI-PDE∆1. The PCR products were digested with appropriate restriction enzymes and subcloned into the corresponding regions of the pBluescript II SK + containing cGI-PDE∆1. These mutant clones were sequenced and then further subcloned into pQE-30 for expression.
Western blotting
Bacterial proteins were separated by SDS\PAGE using 10 % acrylamide and transferred electrophoretically (120 mA for 3 h) on to Immobilon P membrane. A solution of 5 % (w\v) dried milk in Tris-buffered saline (TBS : 10 mM Tris\HCl, pH 8.0, 150 mM NaCl) was used to block the membrane. The primary anti-PDE3A antibody [21] was diluted 1 : 500 in TBS and incubated with membranes at room temperature for 1 h. Membranes were washed three times with TBS containing 0.05 % (v\v) Nonidet P40 and once with TBS, before incubation with secondary antibody conjugated with alkaline phosphatase and detection of immune complexes (Promega, Unionville, ON, Canada). 
Measurement of PDE activity
Photoaffinity labelling of proteins by [ 32 P]cGMP
The method used has been described previously [21] . Briefly, incubation mixtures (0.1 ml) containing 80-100 µg of total bacterial supernatant protein in Buffer A and 5 µCi of [$#P]cGMP (33 nM after dilution) were stirred at 0 mC for 15 min in the dark and then for a further 15 min under UV light. The proteins were precipitated with trichloroacetic acid and analysed by SDS\PAGE (10 % acrylamide). Autoradiography was performed using Kodak X-OMAT AR film.
RESULTS
Cloning, bacterial expression and purification of the human platelet cGI-PDE
Degenerate primers, based on platelet peptide sequences, and purified platelet mRNA were used in an RT-PCR reaction to determine whether the platelet PDE3 enzyme was distinct from the previously cloned human cardiac enzyme [16] . An 800 bp PCR product was generated and cloned into pBluescript II SK + . Nine independent clones were sequenced in both directions, and
Figure 2 Purification of cGI-PDE deletion mutants by nickel-resin column chromatography or immunoprecipitation
E. coli expressing cGI-PDE deletion mutants were harvested and lysed by sonication. After centrifugation at 100 000 g, the His 6 -tagged proteins were purified either by nickel-resin column chromatography or by immunoprecipitation. (a) Soluble protein from E. coli expressing cGI-PDE∆1 (lane 1) was loaded on to a nickel-resin column to bind histidine-containing proteins. After removal of unbound protein (lane 2) and a series of increasingly stringent washes (lanes 3-5), purified protein was eluted from the column (lanes 6 and 7) (see the Experimental section). Protein was analysed by SDS/PAGE ; a Coomassie Blue-stained gel is shown.
(b) Immunoblots of supernatants from bacteria expressing cGI-PDE deletion mutants are shown (lanes 1-3) . Purification of the expressed proteins from the supernatants was achieved by immunoprecipitation and the immunoprecipitates were then analysed by immunoblotting (lanes 4-6). Lanes 1 and 4, cGI-PDE∆1 (∆1) ; lanes 2 and 5, cGI-PDE∆1∆i (∆1∆i) ; lanes 3 and 6, cGI-PDE∆2 (∆2). The positions of protein standards are shown on the left (see the Experimental section).
shown to be identical with nucleotide residues 1982-2752 of the cardiac enzyme (PDE3A). This established that both the platelet and cardiac forms of PDE3 are derived from the same gene. However, this result does not exclude the possibility of alternate splicing of the platelet enzyme at the N-terminus. Sequence-specific primers were selected for RT-PCR amplification of the C-terminal half of the platelet enzyme, including the whole of the catalytic domain (Figure 1a) . The 1769 bp PCR product (see Figure 1a , photograph insert), which represents amino acids 560-1141 of the cardiac enzyme, was cloned into the pBluescript II SK + vector for sequencing. A BamHI\KpnI cDNA fragment was inserted into the corresponding restriction sites of the bacterial expression vector pQE-30. A His ' -tagged protein representing a truncated form of platelet cGI-PDE (cGI-PDE∆1) was expressed to high levels in E. coli. A further deletion mutant, cGI-PDE∆2, containing amino acid residues 659-1141, was constructed by replacing the forward PCR primer (see the Experimental section). In addition, the deletion of the 44-aminoacid insert from the catalytic domain was achieved by selective PCR amplification of upstream and downstream regions (cGIPDE∆1∆i). Amino acid residues surrounding the insert (-PI[insert]LS-) were conserved by incorporating an Afl II restriction site into primers 3 and 4 ( Figure 1b) .
The His ' -tagged proteins were purified from bacterial supernatants using nickel-resin column chromatography (Figure 2a ) or were selectively immunoprecipitated using anti-PDE3A antibody that binds to the C-terminal 14 amino acids of the enzyme [21] . An immunoblot of the immunoprecipitates (Figure 2b ) indicated that the apparent molecular masses of the cGI-PDE∆1, cGI-PDE∆1∆i and cGI-PDE∆2 mutants were higher (80, 75 and 66 kDa respectively) than their calculated molecular masses (67, 62 and 56 kDa respectively). The decrease in electrophoretic mobility of these fusion proteins probably results from the presence of the N-terminal His ' tag.
Photoaffinity labelling of bacterial extracts expressing platelet cGI-PDE deletion mutants
The cGI-PDE∆1 and cGI-PDE∆2 mutants were readily photolabelled by [$#P]cGMP in proportion to the amounts of expressed protein present (compare Figure 2b , lanes 1 and 3, with Figure 3 , lanes 2 and 4). Despite the fact that the cGI-PDE∆1∆i mutant protein was expressed to the same level as cGI-PDE∆1, photolabelling of the former by [$#P]cGMP was much weaker than the latter ( Figure 3, lane 3) . All three photolabelled species were absent from bacterial lysate transformed with the control pQE-30 vector alone ( Figure 3, lane 1) . These results indicate that 
Table 2 Specificity of the effects of PDE inhibitors on cGI-PDE∆1, cGI-PDE∆2 and platelet cGI-PDE
Immunoprecipitates of cGI-PDE from platelets and E. coli expressing cGI-PDE deletion mutants were incubated with 0.5 µM cAMP and the indicated PDE inhibitors for 5 min at 30 mC. Results are meanspS.E. from assays carried out in triplicate.
Inhibition of cAMP hydrolysis (%)
Inhibitor cGI-PDE∆1 cGI-PDE∆2 Platelet cGI-PDE
Figure 4 Phosphodiesterase activities of expressed cGI-PDE∆1 and cGIPDE∆1∆i
The mutant enzymes were immunoprecipitated from bacterial extracts, as described in the Experimental section and assayed for PDE activities. although the expressed N-terminal deletion mutants retained the ability to bind cGMP, removal of the 44 amino-acid-insert from the catalytic domain greatly reduced cGMP binding. Thus cGMP binds to the 62 kDa C-terminal part of PDE3 and, for structural or other reasons, the 44-amino-acid insert facilitates this interaction. The effects of PDE3 inhibitors on the photolabelling of cGI-PDE∆1 and cGI-PDE∆2 were studied. Lixazinone, milrinone and cGMP, all of which inhibit the activity of intact cGI-PDE, suppressed photolabelling of these deletion mutants by [$#P]cGMP (Figure 3b) . These results confirm that all three compounds interact with the C-terminal part of the enzyme containing the catalytic domain.
Comparison of the enzymic properties of cGI-PDE deletion mutants with that of the intact platelet enzyme
Nickel-resin-purified cGI-PDE∆1 was assayed for enzyme activity. Kinetic analysis indicated that the K m values for cAMP and cGMP hydrolysis were 153 nM and 175 nM respectively, and that the ratio of V max for cGMP\V max for cAMP was 0.36. On the basis of the ratios of V max \K m , the inhibition of cGI-PDE∆1 by lixazinone was mixed, with approximately equal competitive and uncompetitive components. Although good kinetic plots were obtained, the enzyme activity of the nickelresin-purified preparation was unstable and was lost within 2-3 days when the enzyme was stored at 4 mC. The sensitivity of the nickel-resin to strong reducing agents, chelating agents and ionic detergents restricted the steps that could be taken to stabilize the enzyme during purification, and dialysis to remove the high concentration of imidazole used to elute the enzyme may have increased the likelihood of inactivation. For these reasons, this method was not routinely used and measurement of enzyme activity in immunoprecipitates was adopted for comparison of the expressed mutant enzymes with the platelet enzyme. The immunoprecipitation procedure provided a more rapid means of enzyme purification that minimized the risk of proteolysis.
The kinetic properties of the immunoprecipitated cGI-PDE∆1 mutant were very similar to those of the nickel-resin-purified enzyme. The K m values for hydrolysis of cAMP and cGMP were 182p12 nM and 153p12 nM respectively, whereas, the ratio of V max for cGMP\V max for cAMP was 0.37p0.05 (Table 1) . Since the latter value was very different from published results with the intact cGI-PDE [23] , we directly compared the K m values and V max ratios of our expressed truncation mutants with that of the immunoprecipitated intact platelet enzyme (Table 1) . A trend towards progressively lower K m values accompanied the deletion of N-terminal sequences from cGI-PDE. Although both cGI-PDE∆1 and cGI-PDE∆2 showed significantly lower K m values for cAMP and cGMP than intact enzyme, only the K m of cGI-PDE∆2 for cGMP was significantly lower than that of cGI-PDE∆1 (P 0.05, Student's t test). Moreover, successive deletions of the N-terminus led to an increase in the ratio V max for cGMP\V max for cAMP from 0.16p0.01 in intact cGI-PDE, to 0.37p0.05 in cGI-PDE∆1 and to 0.49p0.04 in cGI-PDE∆2. Thus our results indicate that loss of the N-terminus enhanced the hydrolysis of cGMP relative to that of cAMP, implying that N-terminal sequences may exert a selective effect on the activity of the catalytic domain.
The effects of PDE3 inhibitors on the immunoprecipitated enzymes were studied. Lixazinone showed the same pattern of mixed inhibition of immunoprecipitated cGI-PDE∆1 as it did with the nickel-resin-purified enzyme (not shown). However, in the case of the immunoprecipitated platelet enzyme, inhibition
Figure 5 Site-directed mutagenesis of the 44-amino-acid insert within the catalytic domain of cGI-PDE∆1
(a) The 44 amino acid inserts from rat adipocyte PDE3B (RA cGI-PDE) and human cardiac PDE3A (HC cGI-PDE) were aligned to identify conserved amino acid residues. Selected residues were replaced with alanine by site-directed mutagenesis of cGI-PDE∆1. The mutants shown were cloned and expressed in E. coli (see Experimental section). by lixazinone could be characterized as competitive or predominantly competitive. This kinetic profile was distinct from that of the expressed cGI-PDE∆1. Measurements of IC &! values for inhibition of cAMP hydrolysis by lixazinone and milrinone (Table 1) indicated three-fold increases for the deletion mutants cGI-PDE∆1 and cGI-PDE∆2, relative to the intact platelet enzyme. This must largely reflect decreases in the K m for cAMP rather than reduced affinities for the inhibitors. Comparison of the effects of selective inhibitors of PDEs 2, 3, 4 and 5 indicated that the specificity for PDE3 inhibitors resides in the expressed C-terminal fragment of the enzyme and is not significantly affected by removal of the N-terminus ( Table 2) .
Immunoprecipitates of cGI-PDE∆1 and cGI-PDE∆1∆i containing similar amounts of immunoreactive protein (Figure 4a ) were compared with respect to their abilities to hydrolyse cAMP and cGMP (Figures 4b and 4c) . Despite its limited capacity for binding [$#P]cGMP, no enzyme activity was detected in cGIPDE∆1∆i.
Site-directed mutagenesis of the 44-amino-acid insert in cGI-PDE∆1
Alignment of the 44-amino-acid inserts of human cardiac PDE3A and rat adipocyte PDE3B showed that 15 amino acid residues
Figure 6 Enzymic properties of site-directed mutants of cGI-PDE∆1
The expressed mutant enzymes were immunoprecipitated from bacterial extracts. were conserved (Figure 5a) . Analysis of the sequences of PDE3A and PDE3B according to Garnier et al. [24] was used to identify conserved regions with potential structural roles. A probable β-turn was located at the C-terminus of the insert (YGC) and a possible β-turn at the N-terminus (PGL). Two residues in each of these sequences were replaced with alanine residues (Figure 5a) . A region containing a cluster of negative charges (SDSDS), as well as a conserved downstream glycine residue were also mutated (Figure 5a ). Photolabelling of these mutants with [$#P]cGMP was unaffected in four of the five examined (Figure 5b ). In these experiments, Western blot analysis of the immunoprecipitates permitted correlation of the extent of photolabelling with the amount of expressed protein used in each sample (Figure 5c ). Despite the presence of sufficient amounts of expressed protein, the P1A G2A mutant remained very poorly photolabelled relative to the cGI-PDE∆1 control (Figure 5b, compare lanes 2 and 5) . Cyclic nucleotide hydrolytic activities of immunoprecipitates of these mutants were compared with those of immunoprecipitates of cGI-PDE∆1 ( Figure 6 ). The results indicated that both cAMP and cGMP hydrolysis by the P1A G2A and Y42A G43A mutants were markedly reduced relative to cGI-PDE∆1 and the other mutants (Figure 6a ). The ratio of cAMP to cGMP hydrolysis, at 0.5 µM substrate concentrations, was unchanged by any of these alanine substitutions. Moreover, the inhibitory effect of 0.1 µM lixazinone was very similar for all the mutant enzymes examined and was not diminished in the P1A G2A and Y42A G43A mutants despite their lower enzyme activities ( Figure 6 ). These results suggest that the 44-amino-acid insert may not be critical for inhibition of the enzyme.
DISCUSSION
Purified platelet mRNA and degenerate PCR primers, based on published platelet peptide sequences [16] , were used to clone a fragment of platelet PDE3. The nucleotide sequence of this partial clone was identical with a segment of the previously cloned human cardiac enzyme [16] , indicating that both platelet and cardiac forms of PDE3 were derived from the same gene (PDE3A). Despite this common origin, fundamental differences exist between the platelet and cardiac enzymes. Platelet PDE3 is cytosolic with a subunit molecular mass of about 110 kDa [7, 21] , whereas the cloned cardiac enzyme is larger (126 kDa) and appears to be predominantly membrane-associated [25] . Moreover, the PDE3 inhibitor, vesnarinone, has been reported to distinguish between the PDE3 enzymes from human heart and platelets, preferentially inhibiting the former [26] . To date, two PDE3 genes have been identified [16, 17] and shown to be expressed in a tissue-specific manner. As defined in the latest nomenclature [11] , the PDE3A gene is expressed in vascular smooth muscle, platelets and cardiac muscle, whereas PDE3B is found predominantly in adipose and liver cells. Recently, a 74 kDa soluble human placental PDE was cloned [27] and found to be identical in sequence with the C-terminus of the human cardiac enzyme. Northern blots and RNase protection assays identified two transcripts (4.4 kb and 7.6 kb) in human placenta. The smaller transcript was generated from an alternate transcriptional start site and encoded the 74 kDa cytosolic enzyme, whereas the larger 7.6 kb transcript coded for a membraneassociated enzyme. A comparable relationship between the soluble platelet and particulate cardiac enzymes may exist, given that two transcripts have also been detected in human erythroleukaemia (HEL) cells, a megakaryocytic human cell line that expresses many platelet proteins [28] . Thus the presence of an additional transcriptional start site or alternate splicing at the N-terminus of the PDE3A gene could account for the differences observed between the platelet and cardiac isoforms of PDE3. Sequences corresponding to the N-terminus of the cloned membrane-bound cardiac enzyme have very recently been amplified from platelet mRNA [28] , but this does not resolve the identity of the N-terminus of the smaller, soluble platelet enzyme.
We have cloned and expressed the C-terminal half of platelet PDE3A (cGI-PDE∆1) in the E. coli strain M15. Since the Nterminus of the platelet cGI-PDE remains to be defined and is unlikely to be identical with that of the cloned cardiac enzyme, N-terminal truncation mutants of platelet cGI-PDE were compared with the full-length native platelet enzyme. To facilitate rapid isolation of the undegraded enzymes, immunoprecipitates were isolated and compared with respect to enzyme kinetics and inhibitor sensitivity. Our results demonstrate that K m values for the hydrolysis of cAMP and cGMP were significantly lower for the N-terminal deletion mutants than for the intact enzyme. Other groups have also reported on the effects of N-terminal deletions in the PDE3A gene. Pillai et al. [29] demonstrated that truncated forms of the cardiac enzyme expressed in yeast hydrolysed cAMP with K m values higher than that of the expressed intact cardiac enzyme. Kasuya et al. [27] expressed the 74 kDa placental cGI-PDE in a baculovirus system and reported that, although the K m value for cAMP was unchanged, that for cGMP was increased to 3.27p1.75 µM. However, in a very recent study of enzymes expressed in Sf 9 cells [30] , kinetic analysis of two N-terminal deletion mutants of cardiac PDE3 did not demonstrate any significant difference in the K m for cAMP for these mutants, relative to the intact expressed cardiac enzyme (0.15-0.22 µM). There are several possible explanations for the differences between our kinetic results and those reported by others. First, our results were derived from enzymes purified by immunoprecipitation or nickel-resin chromatography and were not assayed in crude homogenates. Thus it is possible that extracts of yeast or Sf 9 cells contain proteins or enzymes capable of modifying the activity of the expressed cGI-PDEs. In addition, the deletion mutants used in our studies are 27 to 77 residues shorter than those discussed above [29, 30] . Finally, differences between investigators in terms of the PDE assay conditions used (Mg# + versus Mn# + ) and the protein expression systems used (yeast versus baculovirus versus E. coli ) may have contributed to differences in the kinetic results.
Shortly after completion of the present study, Cheung et al. [28] reported the isolation of cDNA clones expressing PDE3 sequences from a HEL cell library. The clones were 100 % identical at the nucleotide level with the cardiac enzyme. These investigators contend that N-terminal truncated forms of these clones expressed enzymes with K m values that were virtually identical with that of the purified platelet enzyme. Since it is well established that purification of platelet PDE3 results in the isolation of proteolysed forms [6, 23] , it is quite likely that the reported K m values for ' intact ' enzyme are representative of PDE3 fragments. Indeed, the K m value of 0.2 µM [28] is consistent with our value of 0.18 µM for the truncated enzyme. As previously demonstrated [21] , the immunoprecipitation procedure utilized in the present study permits the isolation of nonproteolysed platelet PDE3 enzyme, which can then be directly compared with various truncation mutants.
The K m values obtained for hydrolysis of cAMP and cGMP by immunoprecipitates of intact platelet enzyme were 398p50 nM and 252p16 nM respectively. The respective values given in the literature for these two parameters using the platelet enzyme are quite variable, for example : 0.18 µM and 0.02 µM [6] , 0.20 µM and 0.30 µM [23] and 1.0 µM for cAMP [31] . As discussed above, it is likely that some of these published values represent the enzyme activities of fragments rather than intact cGI-PDE. PDE3 is known not only to have a high affinity for cGMP, but also a low ratio of the V max for cGMP to that for cAMP [11] . We therefore compared the cGMP hydrolytic abilities of our Nterminal deletion mutants with those of the intact platelet enzyme. Our results indicated that as N-terminal sequences were deleted, a progressively lower K m for cGMP was generated and a concomitant three-fold increase in the ratio of V max for cGMP\ V max for cAMP was detected. Thus deletion of sequences from the N-terminus of platelet PDE3 increased the activity of the enzyme towards cGMP relative to cAMP. This implies that directly or indirectly, the N-terminal sequences in part determine the substrate specificity of the enzyme.
A distinguishing feature of the PDE3 gene family is the presence of a 44-amino-acid insertion located within the catalytic domain. The function of this insert, which bears no relationship to other sequences currently in the protein databases, is unknown, though it initially seemed reasonable to speculate that it had a role in the unique properties of the PDE3 family. Although removal of this insert destroyed enzyme activity, a limited ability to bind cGMP, as detected by photolabelling, was retained. Structural analysis of the 44-amino-acid inserts of human cardiac and rat adipocyte enzymes [24] identified a high potential for a β-turn at the C-terminus of the inserts and a possible β-turn at the N-terminus. Site-directed mutagenesis of pairs of amino acids in either of these putative β-turns markedly decreased enzyme activity, though cGMP binding, as determined by photoaffinity labelling, was inhibited only by mutagenesis of the N-terminal insert residues. Mutagenesis of a conserved cluster of negatively charged residues in the centre of the insert was without effect. Although our results did not identify any specific functional role for amino acid residues in the insert, though it seems clear that the insert is required to preserve an effective catalytic domain structure.
The effects of the PDE3 inhibitor lixazinone, on the cAMP hydrolytic activities of intact platelet cGI-PDE and the Nterminal truncation mutants, were studied. Our results demonstrated that lixazinone increased the K m of the intact platelet enzyme, but left the V max largely unaffected, indicating that it is a competitive inhibitor. In contrast, mixed inhibition with roughly equal competitive and uncompetitive components was seen with the cGI-PDE∆1 deletion mutant. The previously reported inhibitory effect of lixazinone on platelet cGI-PDE purified by DEAE-cellulose chromatography [32] also indicated a mixed pattern of inhibition, similar to that obtained for the Nterminal deletion mutant, cGI-PDE∆1. Since purification of PDE3 by this method is known to generate proteolytic fragments, it is possible that the inhibitory profile reported in [32] is representative of a PDE3 fragment rather than the intact platelet enzyme. The high inhibitory potency of lixazinone is due to the molecular interaction between the compound and a bulktolerant, lipophilic region of the enzyme [33] . Since inhibition by this compound changes from predominantly competitive, for the intact enzyme, to mixed in the deletion mutant, it is possible that removal of the N-terminus provides the inhibitor with access to an alternate binding site.
Regardless of the mechanism, it is clear that the N-terminal deletion mutants retain the capacity of the intact enzyme to respond selectively to PDE3 inhibitors. Moreover, no changes in inhibition of the enzyme by lixazinone were seen in site-directed mutants of the 44-amino-acid insert. Thus the characteristic inhibitor profile of PDE3 probably reflects the structure of the catalytic domain, though C-terminal sequences, which were not deleted in this study, could also be involved.
